The burden of type 2 diabetes in Europe : Current and future aspects of insulin treatment from patient and healthcare spending perspectives
Copyright © 2020. Published by Elsevier B.V..
Due to the progressive nature of type 2 diabetes (T2DM), initiation of insulin therapy is very likely in the disease continuum. This article aims at highlighting the current situation with regard to insulin therapy in people with T2DM in Europe and at presenting the associated unmet need. Challenges for both people with T2DM and healthcare professionals include clinical inertia also derived from fear of hypoglycaemia, weight gain and injections as well as increased need for a comprehensive diabetes management. We compare national and international guidelines and recommendations for the initiation and intensification of insulin therapy with the real-world situation in six European countries, demonstrating that glycaemic targets are only met in a minority of people with T2DM on insulin therapy. Furthermore, this work evaluates currently recorded numbers of people with T2DM treated with insulin in Europe, the proportion not achieving the stated glycaemic targets and thus in need to enhance insulin therapy e.g. by a change in means of insulin delivery including, but not limited to, insulin pens, wearable mealtime insulin delivery patches, patch pumps, and conventional insulin pumps with continuous subcutaneous insulin infusion.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
---|---|
Enthalten in: |
Diabetes research and clinical practice - 161(2020) vom: 15. März, Seite 108053 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ceriello, Antonio [VerfasserIn] |
---|
Links: |
---|
Themen: |
Burden |
---|
Anmerkungen: |
Date Completed 17.06.2020 Date Revised 17.06.2020 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.diabres.2020.108053 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM306296950 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM306296950 | ||
003 | DE-627 | ||
005 | 20231225123042.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.diabres.2020.108053 |2 doi | |
028 | 5 | 2 | |a pubmed24n1020.xml |
035 | |a (DE-627)NLM306296950 | ||
035 | |a (NLM)32035117 | ||
035 | |a (PII)S0168-8227(19)31760-7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ceriello, Antonio |e verfasserin |4 aut | |
245 | 1 | 4 | |a The burden of type 2 diabetes in Europe |b Current and future aspects of insulin treatment from patient and healthcare spending perspectives |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.06.2020 | ||
500 | |a Date Revised 17.06.2020 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020. Published by Elsevier B.V. | ||
520 | |a Due to the progressive nature of type 2 diabetes (T2DM), initiation of insulin therapy is very likely in the disease continuum. This article aims at highlighting the current situation with regard to insulin therapy in people with T2DM in Europe and at presenting the associated unmet need. Challenges for both people with T2DM and healthcare professionals include clinical inertia also derived from fear of hypoglycaemia, weight gain and injections as well as increased need for a comprehensive diabetes management. We compare national and international guidelines and recommendations for the initiation and intensification of insulin therapy with the real-world situation in six European countries, demonstrating that glycaemic targets are only met in a minority of people with T2DM on insulin therapy. Furthermore, this work evaluates currently recorded numbers of people with T2DM treated with insulin in Europe, the proportion not achieving the stated glycaemic targets and thus in need to enhance insulin therapy e.g. by a change in means of insulin delivery including, but not limited to, insulin pens, wearable mealtime insulin delivery patches, patch pumps, and conventional insulin pumps with continuous subcutaneous insulin infusion | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Burden | |
650 | 4 | |a Europe | |
650 | 4 | |a Insulin therapy | |
650 | 4 | |a Type 2 diabetes mellitus | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Insulin |2 NLM | |
700 | 1 | |a deValk, Harold W |e verfasserin |4 aut | |
700 | 1 | |a Guerci, Bruno |e verfasserin |4 aut | |
700 | 1 | |a Haak, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Owens, David |e verfasserin |4 aut | |
700 | 1 | |a Canobbio, Michela |e verfasserin |4 aut | |
700 | 1 | |a Fritzen, Katharina |e verfasserin |4 aut | |
700 | 1 | |a Stautner, Constantin |e verfasserin |4 aut | |
700 | 1 | |a Schnell, Oliver |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetes research and clinical practice |d 1993 |g 161(2020) vom: 15. März, Seite 108053 |w (DE-627)NLM01260335X |x 1872-8227 |7 nnns |
773 | 1 | 8 | |g volume:161 |g year:2020 |g day:15 |g month:03 |g pages:108053 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diabres.2020.108053 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 161 |j 2020 |b 15 |c 03 |h 108053 |